NMR spectroscopy of anticancer platinum drugs.
The focus of this review is on recently published papers (2000-2005) where NMR spectroscopy has been applied as the principal method in the study of anticancer platinum drugs. The paper gives an overview of the basic NMR techniques particularly relevant for studying interaction between platinum compounds and nucleic acid constituents. The latest NMR studies on the well-known anticancer drug cisplatin, with focus on kinetics and cisplatin-DNA structures are reported. Also cisplatin analogues clinically approved or currently in clinical trials are discussed. In addition two new classes of anticancer platinum drugs are described: trans-oriented Pt iminoether complexes and multinuclear Pt complexes. Reaction kinetics and structural changes induced by these novel Pt drugs are discussed in relation to cisplatin. NMR studies of non-DNA platinum drug targets including peptides, proteins and phospholipid membranes are also treated.
Vinje
Jo
J
Department of Chemistry, University of Bergen, Bergen, Norway.
Sletten
Einar
E
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003432:Cross-Linking Reagents / Q000737:chemistry; D018736:DNA Adducts / Q000737:chemistry*; D004273:DNA, Neoplasm / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009696:Nucleic Acids / Q000737:chemistry; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism; D017671:Platinum Compounds / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D003432:Cross-Linking Reagents; D018736:DNA Adducts; D004273:DNA, Neoplasm; D009696:Nucleic Acids; D009944:Organoplatinum Compounds; D017671:Platinum Compounds